BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bizengri (Zenocutuzumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bizengri (Zenocutuzumab)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02912949-2821@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bizengri (Zenocutuzumab): Phase 2 readout est. (NCT02912949)
DESCRIPTION:Bizengri (Zenocutuzumab)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumor
 s Harboring an NRG1 Fusion (eNRGy)\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenocutuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 2912949
URL:https://assetmemo.bio/drug/zenocutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
